|
EORTC AISBL / IVZW |
|
|
EORTC AISBL / IVZW |
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 11011 | Early phase II study on BNCT in metastatic malignant melanoma using the boron carrier BPA |
| 18981 | TRIAL 18981 TEMOZOLOMIDE versus TEMOZOLOMIDE + WHOLE BRAIN RADIATION IN STAGE IV MELANOMA PATIENTS WITH ASYMPTOMATIC BRAIN METASTASES |
| 16005 | Open label Phase II study of E7070 in patients with metastatic melanoma (stage IV). EORTC protocol 16005-18002 |
| 18951 | Randomized phase III trial. Treatment of metastatic melanoma with DTIC, CDDP and IFN-alpha with or without IL-2. |
| 18902 | Study on the effect of elective lymph node dissection after wide local excision for head and neck melanomas (0.76 to 4.00 mm thick): A phase III randomized study (Jointly with the EORTC Melanoma Cooperative Group) |
| 04892 | Essais cliniques phase II d'une nouvelle nitrosour‚e: la Cyst‚mustine dans les m‚lanomes et les reins |
| 04891 | Essais cliniques phase II d'une nouvelle nitrosourée: la Cystémustine dans les poumons, les adénocarcinomes colo-rectaux, les gliomes, les mélanomes, les reins, les sarcomes des parties molles et les tumeurs de la tête et du cou. |
| 16893M | Phase II trial of GR63178A in patients with malignant melanoma |
| 16891M | Phase II trial of CL286,558 in patients with malignant melanoma |
| 18891 | Phase II study of toremifene inpatients with advanced melanoma |
| 18881 | Phase II trial of fotemustine in patients with advanced malignant melanoma |
| 18871 | Adjuvant phase III trial in malignant melanoma comparing Interferon r alpha-2 to r gamma to a control group after surgical removal of either high risk primary (> 3 mm) or curative resection of lymph node metastasis (stage IIB) (Jointly with the Deutsche Krebsgesellschaft - Protocol DKG 80-1) |
| 16871M | Phase II study of DuP 785 (NSC 368390) in patients with advanced malignant melanoma |
| 16864G | Phase II Chemotherapy with Flavone Acetic Acid in Patients with Advanced Malignant Melanoma (Summary Last Modified 03/88) |
| 04861 | Etude clinique phase II 4' -0-tetrahydropyranyl adriamycine (THP-ADM-1609 RB) |
| 16862 | EARLY CLINICAL TRIAL MITOZOLOMIDE VS TCNU IN MELANOMA |
| 18852 | PILOT PHASE II STUDY ON RECOMBINANT Interferon ALPHA 2 IN ADVANCED MALIGNANT MELANOMA. |
| 18851 | Randomized phase II study of topical treatment with DNCB followed by systemic DTIC alone in melanoma patients with contineous (+/-other) metastases. |
| 18841 | Randomized phase II trial of two platinum derivatives : carboplatin (CBDCA) vs iproplatin (CHIP) in advanced malignant melanoma. |
| 18832 | Randomized phase III trial comparing surgery with or without prophylactic isolation perfusion for stage I high risk (> 1.5 mm thickness) malignant melanoma of the limbs (Jointly with WHO and NAPG) |
| 04832 | Phase II Chemotherapy with 4-Demethoxydaunorubicin for Lymphoma (Summary Last Modified 05/88) |
| 18831 | Phase II study of Tamoxifen in post-menopausal women with advanced melanoma |
| 18781 | A controlled trial on long term immunotherapy comparing two BCG preparations for stage I high risk malignant melanoma |
| 16032 | Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma |
| 18961 | Adjuvant ganglioside GM2-KLH/QS-21 Vaccination Post-operative adjuvant ganglioside GM2-KLH/QS-21 vaccination treatment vs observation after resection of primary cutaneous melanoma (AJCC stage II, T3-T4N0M0), a 2-arm multicenter randomized phase III trial |
| 18991 | TRIAL 18991 ADJUVANT PEG-INTRON TREATMENT IN STAGE III MELANOMA versus OBSERVATION AFTER REGIONAL LYMPH NODE DISSECTION A Multicenter Randomized Phase III trial |
| 18952 | Randomized phase III trial. Post-operative adjuvant Interferon-alpha 2b (Intron-A) treatment after resection of thick primary melanoma and/or regional lymphnode metastases "intermediate-high dose" vs "intermediate-low dose" Interferon-alpha vs observation. |
| 90061 | Multicenter parallel phase II trial of BI 2536 administrered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions (NOCI) |
| 18071 | Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma : A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group. |
| 16921M | Phase II trial with Taxotere in patients with malignant melanoma |
| 16901M | Phase II trial of Gemcitabine (LY 188011) in patients with melanoma |